Menu
Back to Journals » OncoTargets and Therapy » Volume 9
Original Research
Survival benefit and safety of the combinations of FOLFOXIRI ± bevacizumab versus the combinations of FOLFIRI ± bevacizumab as first-line treatment for unresectable metastatic colorectal cancer: a meta-analysis
| Total article views | HTML views | PDF downloads | Totals | ||
|---|---|---|---|---|---|
| 8,531 | Dovepress* | 7,417+ | 1,174 | 8,591 | |
| PubMed Central* | 1,114 | 420 | 1,534 | ||
| Totals | 8,531 | 1,594 | 10,125 | ||
| *Since 4 August 2016 | |||||
View citations on PubMed Central and Google Scholar